Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients

Inclusion Criteria: * Patients having a kidney transplant since at least 6 months but for no longer than 5 years. * Patients in a stable condition in terms of graft function * Patients currently receiving EC-MPS and CsA with or without corticosteroids as part of their immunosuppressive regimen for at least 1 month prior to Baseline * Females of childbearing potential must have a negative serum pregnancy test prior to study inclusion. If positive, the patient will not be enrolled. Effective contraception must be used during the trial. Exclusion Criteria: * Patients with any known hypersensitivity to EC-MPS or everolimus or other components of the formulation (e.g., lactose) * Patients with a history of severe rejection (according to BANFF criteria) within 3 months of enrollment in this trial. * Changes to the immunosuppressive regimen during the last 3 months due to immunologic reasons. * Patients with thrombocytopenia (platelets \<100,000/mm3), with an absolute neutrophil count of \<1,500/mm3 and/or leukocytopenia (leukocytes \<4,500/mm3), and/or hemoglobin \<9.0 g/dL at baseline. * Patients with proteinuria at baseline (\> 1g/d) Other protocol-defined inclusion/exclusion criteria may apply